Core Insights - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C levels [1][3] - The company aims to address the unmet need for safe and well-tolerated LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [3] Upcoming Investor Conferences - NewAmsterdam management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, with CFO Ian Somaiya speaking at 3:50 p.m. ET [4] - The company will also be present at Citi's 2025 Global Healthcare Conference on December 3, 2025, where CEO Michael Davidson and CFO Ian Somaiya will speak at 3:15 p.m. ET [4] - Additionally, NewAmsterdam will attend the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, with CEO Michael Davidson and CFO Ian Somaiya participating at 8:00 a.m. ET [4] Company Overview - NewAmsterdam Pharma is dedicated to improving patient care in populations with metabolic diseases where current therapies are insufficient or poorly tolerated [3] - The company is conducting multiple phase 3 trials for obicetrapib, an oral, low-dose CETP inhibitor, which is being tested alone and in combination with ezetimibe as an adjunct to statin therapy [3]

Core Viewpoint - Tempest Therapeutics, Inc. has entered into a definitive agreement for a registered direct offering of common stock, aiming to raise approximately $4.25 million, with potential additional proceeds of up to $4.1 million from short-term unregistered warrants [1][3]. Group 1: Offering Details - The company will sell 1,172,414 shares of common stock at an offering price of $3.625 per share [1]. - Concurrently, short-term unregistered warrants will be issued to purchase an additional 1,172,414 shares at an exercise price of $3.50 per share, which will be immediately exercisable and expire in eighteen months [1][3]. - The closing of the offering is expected to occur on or about November 25, 2025, subject to customary closing conditions [1]. Group 2: Financial Implications - The aggregate gross proceeds from the offering are expected to be approximately $4.25 million before deducting fees and expenses [3]. - If the short-term unregistered warrants are fully exercised, the potential additional gross proceeds could reach approximately $4.1 million [3]. - The net proceeds from this offering are intended primarily for working capital and general corporate purposes [3]. Group 3: Regulatory and Compliance Information - The shares are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on January 27, 2025 [4]. - The short-term unregistered warrants are offered in a private placement and have not been registered under the Securities Act [5].

Core Insights - UroGen Pharma Ltd. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2-4, 2025 [1][2] - The presentation will take place on December 2, 2025, at 1:00 PM ET in a fireside chat format [2] - UroGen is focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary technologies [3] Company Overview - UroGen Pharma Ltd. is dedicated to treating urothelial and specialty cancers, aiming to provide better treatment options for patients [3] - The company has developed RTGel, a reverse-thermal hydrogel technology that allows for sustained release of medications, potentially enhancing therapeutic effectiveness [3] - UroGen's first product targets low-grade upper tract urothelial carcinoma (LG-UTUC), while its second product is an intravesical solution for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) [3] - The company is headquartered in Princeton, NJ, with operations in Israel [3]

Core Insights - PetVivo Holdings, Inc. has launched PetVivo.ai, an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [1][3][4] - The company is shifting from traditional medical device sales to a high-margin AI Software-as-a-Service (SaaS) model, which offers recurring revenue and scalability [2][5] Industry Context - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet owners making up 57% of all pet owners, who expect modern digital experiences [3] - Veterinary practices currently rely on outdated marketing methods, leading to high customer acquisition costs ranging from $80 to $400 per new client [3][4] Company Strategy - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with engaged pet parents, generating qualified leads at a cost of $3 per pet parent, compared to traditional methods costing $15 to $45 [4][6] - The platform's beta program showed that the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53, achieving significant savings [4][6] Financial Metrics - The platform is expected to achieve gross margins of 80-90% and a lifetime value to customer acquisition cost (LTV/CAC) ratio of 25:1 [6] - Projections indicate that by Year 1, the company could reach $12 million in annual recurring revenue (ARR) with 500 practices, scaling to $360 million ARR with 10,000 practices by Year 5 [6] Market Opportunity - PetVivo.ai targets approximately 30,000 U.S. veterinary practices and over 100,000 globally, with strong scaling potential even under conservative adoption forecasts [5][6] - The launch is seen as a catalyst for re-evaluating the company's valuation, transitioning from traditional medical device revenue multiples of 1-2x to AI SaaS multiples of 15-30x [5][7] Competitive Advantages - PetVivo.ai holds a first-mover advantage with no direct AI competitors and strong two-sided network effects, supported by existing relationships with 1,200 veterinary clinic distributors [7] - Deep integrations with practice management systems are expected to facilitate adoption and reduce onboarding friction [7] Commercial Launch - Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups, offering a 14-day free trial and three pricing tiers [8]

Core Viewpoint - BellRing Brands, Inc. will participate in the Morgan Stanley Global Consumer & Retail Conference on December 2-3, 2025, indicating its active engagement with investors and the market [1]. Company Overview - BellRing Brands, Inc. is a fast-growing consumer brands business focused on the convenient nutrition category, with brands such as Premier Protein and Dymatize [3]. - Premier Protein is recognized as the 1 ready-to-drink protein and convenient nutrition brand, while Dymatize is known for its 1 hydrolyzed protein powder [3]. - The company operates with a mission to change lives through good energy and emphasizes the importance of nutrition for a healthy world [3]. - BellRing's products are distributed in over 90 countries across various channels including club, mass, food, eCommerce, specialty, drug, and convenience [3]. Event Participation - The company will hold a fireside chat with investors at approximately 2:15 p.m. Eastern Time on December 2, 2025, as part of the conference [1]. - Interested parties can access the webcast of the fireside chat through the Investor Relations section of BellRing's website, with a replay available for a limited time [2].

Core Insights - ZenaTech, Inc. has opened a new office in the Washington, D.C. area to enhance its engagement with federal government and defense agencies, aiming to establish a strong federal presence for defense revenue growth [1][2] - The company is expanding its manufacturing facility in Mesa, Arizona, tripling the size to support full U.S. drone assembly, production, and testing, which aligns with its strategy to increase operational capacity and meet the growing demand for advanced UAV systems [2][3] Company Overview - ZenaTech specializes in AI drone technology, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, focusing on mission-critical applications across various sectors including defense, agriculture, and logistics [3][6] - The company operates globally with offices in North America, Europe, Taiwan, and the UAE, and is actively growing its U.S. DaaS business through acquisitions [3] Product Offerings - ZenaTech's drone portfolio includes the ZenaDrone 1000, capable of lifting approximately 40 kg, designed for inspection, surveillance, and reconnaissance applications, and has been tested by the U.S. Air Force and Navy Reserve [5][6] - The IQ Square and IQ Nano drones serve specific functions such as land surveys, infrastructure inspections, and inventory management in GPS-denied environments, showcasing the versatility of ZenaTech's drone solutions [5][6]

Core Insights - Dragonfly Energy Holdings Corp. is expanding its Battle Born® product portfolio with new inverter/chargers, Base Series batteries, and a redesigned mobile app, enhancing its position as a complete power solutions provider across various markets [1][5] Product Expansion - The new Battle Born Inverter/Charger Series features pure sine wave models with advanced power control and inverter assist functions for efficient power management, equipped with Dragonfly IntelLigence® technology and compatible with the Battle Born mobile app for real-time monitoring [2] - The Battle Born Base Series Batteries are designed for a broader, value-conscious market, providing a modern LiFePO₄ alternative to traditional sealed lead-acid units, suitable for portable and auxiliary power needs [3] - The updated Battle Born Mobile App V2.0 offers a redesigned interface and optimized backend for better system control, allowing users to monitor and adjust settings in real time, and introduces RV-C integration for interoperability with third-party platforms [4] Strategic Vision - The CEO of Dragonfly Energy emphasized that the expansion of the product ecosystem marks a pivotal moment in the company's evolution, focusing on delivering a fully integrated power system that enhances customer control and confidence [5] - The new products are available for sale as part of the annual Black Friday sales event, with the mobile app launching on November 28, 2025, and additional product releases planned throughout 2026 [5] Company Overview - Dragonfly Energy is a leader in lithium battery technology, specializing in cell manufacturing, battery pack assembly, and full system integration, with a mission focused on the future deployment of proprietary, nonflammable, all-solid-state battery cells [7]

Core Insights - reAlpha Tech Corp. has acquired Prevu Inc., expanding its real estate footprint into 11 new markets and enhancing its technology-driven platform [1][3] - Prevu is a digital homebuying platform with a rebate-oriented brokerage model, having completed over 1,000 transactions and maintaining a 5-star Google rating [2][4] - The acquisition aims to unify realty and mortgage capabilities, supporting a broader national footprint and enhancing operational capabilities [1][3] Company Overview - reAlpha Tech Corp. is an AI-powered real estate technology company focused on transforming the U.S. real estate services market through an end-to-end platform that integrates brokerage, mortgage, and title services [5] - Prevu operates in major metropolitan markets across 12 states and Washington, D.C., providing a digital platform designed to empower homebuyers with greater control and transparency [4] Strategic Implications - The integration of Prevu's brokerage operations with reAlpha's existing real estate services is expected to accelerate reAlpha's long-term platform strategy and enhance operational efficiency [3] - Both companies share a commitment to modernizing real estate through technology, which is anticipated to create significant opportunities for scaling and delivering value to homebuyers and agents [3][2]

VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Highland Copper Company Inc. (TSXV: HI; OTCQB: HDRSF) (“Highland Copper” or the “Company”) is pleased to announce that it has signed a binding offer from its joint venture partner, Kinterra Copper USA LLC (“Kinterra”), for the sale of the Company’s 34% interest in the White Pine North Project (“White Pine”) for aggregate consideration of approximately US$30 million. This transaction represents a significant milestone in optimizing Highland Coppe ...

Core Insights - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on genetic diseases, aiming to discover, create, test, and deliver transformative medicines [2] Company Overview - Founded in 2015, BridgeBio has a pipeline that spans from early science to advanced clinical trials, with a commitment to applying advances in genetic medicine [2] - The company is staffed by experienced professionals in drug discovery and development [2] Upcoming Events - Management will participate in fireside chats at the Piper Sandler Healthcare Conference on December 2 at 10:30 am EST and the EvercoreISI HealthCONx Conference on December 3 at 3:00 pm EST [3] - Live webcasts of these presentations will be accessible on the BridgeBio website, with replays available for 90 days post-event [1]